Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Parag Jasani

Parag Jasani

FRCPath, MBBS, MRCP

Royal Free London NHS Foundation Trust

The key barrier to making the implementation of bispecific antibodies in CLL possible

The key barrier to making the implementation of bispecific antibodies in CLL possible

Parag Jasani • 23 Sep 2025

Investigating bispecific antibodies in CLL

Investigating bispecific antibodies in CLL

Parag Jasani • 22 Sep 2025

The potential of bispecific antibodies in CLL

The potential of bispecific antibodies in CLL

Parag Jasani • 19 Sep 2025

Personalizing CLL therapy in the frontline

Personalizing CLL therapy in the frontline

Parag Jasani • 13 Feb 2024

NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study

NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study

Parag Jasani • 29 Jan 2024

The current treatment landscape in CLL

The current treatment landscape in CLL

Parag Jasani • 24 Jan 2023

The evolution of treatment for elderly patients with CLL

The evolution of treatment for elderly patients with CLL

Parag Jasani • 24 Jan 2023

Phase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL

Phase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL

Parag Jasani • 24 Jan 2023

What to look forward to at ASCO 2022

What to look forward to at ASCO 2022

Parag Jasani • 22 Jun 2022

NVG-111: a ROR1-targeting bispecific T-cell engager for CLL and MCL

NVG-111: a ROR1-targeting bispecific T-cell engager for CLL and MCL

Parag Jasani • 14 Jun 2022

The rationale behind targeting ROR1 in CLL and MCL

The rationale behind targeting ROR1 in CLL and MCL

Parag Jasani • 14 Jun 2022